biostudies-literatureUnknown147(4)Badrising SKBayer HealthCareThe ALSYMPCA study established a 3.6 month Overall Survival (OS) benefit in metastatic Castration Resistant Prostate Cancer (mCRPC) patients treated with Radium-223 dichloride (Ra-223) over placebo. Here we report clinical outcomes of Ra-223 treatment in a nonstudy population. In this prospective registry, patients from 20 Dutch hospitals were included prior to Ra-223 treatment. Clinical parameters collected included previous treatments and Adverse Events. Primary outcome was 6 months Symptomatic Skeletal Event (SSE)-free survival, while secondary outcomes included Progression-Free Survival (PFS) and Overall Survival (OS). Of the 305 patients included, 300 were evaluable. The mean age was 73.6 years, 90% had ≥6 bone metastases and 74.1% were pretreated with Docetaxel, 19.5% with CabazitaxeInternational journal of cancer1143-1151https://www.ebi.ac.uk/biostudies/studies/S-EPMC7383569biostudies-literatureA prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.PMC7383569Coenen JLLMVegt ELouhanepessy RDvan der Noort VOostdijk ALoosveld OJLBergman AMHamberg PCelik FHaanen JBZwart WWagenaar NZuetenhorst HBeeker ALam MGEHBadrising SKROTOR investigators and the Dutch Uro-Oncology Study group (DUOS15101)falseA prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.The ALSYMPCA study established a 3.6 month Overall Survival (OS) benefit in metastatic Castration Resistant Prostate Cancer (mCRPC) patients treated with Radium-223 dichloride (Ra-223) over placebo. Here we report clinical outcomes of Ra-223 treatment in a nonstudy population. In this prospective registry, patients from 20 Dutch hospitals were included prior to Ra-223 treatment. Clinical parameters collected included previous treatments and Adverse Events. Primary outcome was 6 months Symptomatic Skeletal Event (SSE)-free survival, while secondary outcomes included Progression-Free Survival (PFS) and Overall Survival (OS). Of the 305 patients included, 300 were evaluable. The mean age was 73.6 years, 90% had ≥6 bone metastases and 74.1% were pretreated with Docetaxel, 19.5% with Cabazitaxe2020-01-01T00:00:00Z2020 Aug2025-04-29T10:52:16.699Z2025-04-06T19:42:00.782ZS-EPMC73835693187595610.1002/ijc.32851